15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 22 firms covering Ionis Pharmaceuticals Inc, 18 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $75.00 to $129.00, a moderate spread. The average target of $97.59 sits 76% above the current $55.32. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.81 next quarter toward $-1.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS22 ratings
Moderate Buy
Strong Buy15%
Buy1777%
Hold418%
Sell00%
Strong Sell00%
Based on 22 analysts giving stock ratings to Ionis Pharmaceuticals Inc.
As of Jul, 18 of 22 firms rate IONS a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IONS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.81
Range $-0.93 – $-0.61 · 7 analysts · +32% YoY
Next period, 7 analysts expect Ionis Pharmaceuticals Inc to earn $-0.81 a share (range $-0.93 – $-0.61), versus $-0.61 a year earlier. Full-year consensus is $-2.62, growing to $-1.07 the year after.
REVENUE · NEXT QUARTER
$202.0M
Range $176.7M – $218.0M · 7 analysts · +29% YoY
Revenue is expected to reach $202.0M (range $176.7M – $218.0M), +28.7% year-over-year. Full-year consensus is $890.2M, rising to $1.4B next year.
Top analysts covering Ionis Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IONS.
#1
Jessica Fye
JP Morgan · Rank #64
Buy
$72.00+30.2% to target
Overall win rate
52%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #136
Buy
$90.00+62.7% to target
Overall win rate
46%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$125.00+126.0% to target
Overall win rate
34%
+ Follow
#4
Joseph Stringer
Needham · Rank #168
Buy
$86.00+55.5% to target
Overall win rate
36%
+ Follow
#5
Yaron Werber
TD Cowen
Buy
$94.00+69.9% to target
Coverage
—
+ Follow
IONS stock forecast FAQ
What is IONS's average 12-month price target?+
The 17 analysts with a live target average $97.59 for Ionis Pharmaceuticals Inc over the next 12 months, ranging from a $129.00 high to a $75.00 low.
Is IONS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 22 analyst ratings, 18 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IONS?+
The Street-high target is $129.00 (Leerink Partners), and the Street-low is $75.00 (Goldman Sachs). The average of all 17 active targets is $97.59.
How many Wall Street analysts cover IONS?+
22 analysts have an active rating on Ionis Pharmaceuticals Inc, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering IONS?+
Among analysts who currently cover IONS, Jessica Fye of JP Morgan has the strongest overall Quantellect track record (Rank #64). Their current call is Buy with a $72.00 target.
What is Ionis Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.81 per share (range $-0.93 – $-0.61) across 7 analysts. Full-year EPS is projected at $-2.62, rising to $-1.07 the following year.
How much revenue is Ionis Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $202.0M (range $176.7M – $218.0M). Full-year revenue is projected at $890.2M, growing to $1.4B next year.
Have analysts been upgrading or downgrading IONS lately?+
As of Jul, 18 of 22 firms rate IONS a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IONS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
